Myoglobin Reconstituted with Ni Tetradehydrocorrin as a Methane-Generating Model of Methyl-coenzyme M Reductase

Myoglobin reconstituted with Ni tetradehydrocorrin was investigated as a model of F430-containing methyl-coenzyme M reductase, which catalyzes anaerobic methane generation. The Ni^II tetradehydrocorrin complex has a Ni^II /Ni^I redox potential of -0.34 V vs. SHE and EPR spectroscopy indicates the formation of a Ni^I species upon reduction by dithionite. This redox potential is approximately 0.31 V more positive than that of F430. The Ni^I tetradehydrocorrin moiety is bound to the apo-form of myoglobin to yield the reconstituted protein. Methane gas is generated in the reaction of the model with methyl iodide in the presence of the reconstituted protein under reductive conditions, whereas the Ni^I complex itself does not produce methane gas. This is the first example of a protein-based functional model of F430-containing methyl-coenzyme M reductase.

Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia

A series of 6-acylureido derivatives containing a 3-(pyrrol-2-ylmethylidene)indolin-2-one scaffold were synthesized as potential dual Aurora B/FLT3 inhibitors by replacing the 6-arylureido moiety in 6-arylureidoindolin-2-one-based multi-kinase inhibitors. (Z)-N-(2-(pyrrolidin-1-yl)ethyl)-5-((6-(3-(2-fluoro-4-methoxybenzoyl)ureido)-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (54) was identified as a dual Aurora B/FLT3 inhibitor (IC50 = 0.4 nM and 0.5 nM, respectively). Compound 54 also exhibited potent cytotoxicity with single-digit nanomolar IC50 values against the FLT3 mutant-associated human acute myeloid leukemia (AML) cell lines MV4-11 (FLT3-ITD) and MOLM-13 (FLT3-ITD). Compound 54 also specifically induced extrinsic apoptosis by inhibiting the phosphorylation of the Aurora B and FLT3 pathways in MOLM-13 cells. Compound 54 had a moderate pharmacokinetic profile. The mesylate salt of 54 efficiently inhibited tumor growth and reduced the mortality of BALB/c nude mice (subcutaneous xenograft model) that had been implanted with AML MOLM-13 cells. Compound 54 is more potent than sunitinib not only against FLT3-WT AML cells but also active against sunitinib-resistant FLT3-ITD AML cells. This study demonstrates the significance of dual Aurora B/FLT3 inhibitors for the development of potential agents to treat AML.

Normal and abnormal heme biosynthesis. Part 7. Synthesis and metabolism of coproporphyrinogen-III analogues with acetate or butyrate side chains on rings C and D. Development of a modified model for the active site of coproporphyrinogen oxidase

Analogues of coproporphyrinogen-III have been prepared with acetate or butyrate groups attached to the C and D pyrrolic subunits. The corresponding porphyrin methyl esters were synthesized by first generating a,c-biladienes by reacting a dipyrrylmethane with pyrrole aldehydes in the presence of HBr. Cyclization with copper(II) chloride in DMF, followed by demetalation with 15% H(2)SO(4)-TFA and reesterification, gave the required porphyrins in excellent yields. Hydrolysis with 25% hydrochloric acid and reduction with sodium-amalgam gave novel diacetate and dibutyrate porphyrinogens 9. Diacetate 9a was incubated with chicken red cell hemolysates (CRH), but gave complex results due to the combined action of two of the enzymes present in these preparations. Separation of uroporphyrinogen decarboxylase (URO-D) from coproporphyrinogen oxidase (CPO) allowed the effects of both enzymes on the diacetate substrate to be assessed. Porphyrinogen 9a proved to be a relatively poor substrate for CPO compared to the natural substrate coproporphyrinogen-III, and only the A ring propionate moiety was processed to a significant extent. Similar results were obtained for incubations of 9a with purified human recombinant CPO. Diacetate 9a was also a substrate for URO-D and a porphyrinogen monoacetate was the major product in this case; however, some conversion of a second acetate unit was also evident. The dibutyrate porphyrinogen 9b was only recognized by the enzyme CPO, but proved to be a modest substrate for incubations with CRH. However, 9b was an excellent substrate for purified human recombinant CPO. The major product for these incubations was a monovinylporphyrinogen, but some divinyl product was also generated in incubations using purified recombinant human CPO. The incubation products were converted into the corresponding porphyrin methyl esters, and these were characterized by proton NMR spectroscopy and mass spectrometry. The results extend our understanding of substrate recognition and catalysis for this intriguing enzyme and have allowed us to extend the active site model for CPO. In addition, the competitive action of both URO-D and CPO on the same diacetate porphyrinogen substrate provides additional perspectives on the potential existence of abnormal pathways for heme biosynthesis.

Synthesis of Isomeric Angularly Annealed Dinaphthoporphyrin Systems: Examination of the Relative Positioning and Orientation of Ring Fusion as Factors Influencing the Porphyrin Chromophore

Porphyrins built up from two naphtho[1,2-c]pyrrole subunits and two beta-substituted pyrroles can produce five isomeric dinaphthoporphyrin systems. To gain insights into the effects of ring fusion on extended porphyrin chromophores, all five of these systems were synthesized in isomerically pure form. In four of these syntheses, dihydronaphthopyrroles were used to introduce one or both of the naphthalene subunits, and dehydrogenation with DDQ in refluxing toluene later produced the fully conjugated systems. Naphthopyrroles were also prepared by reacting isocyanoacetate esters with 1-nitronaphthalene in the presence of a phosphazene base. These compounds proved to be less stable than their dihydronaphthopyrrolic counterparts but could still be utilized in these synthetic studies. Three isomeric adj-dinaphthoporphyrin systems were prepared using the MacDonald "2 + 2" condensation or by the cyclization of a,c-biladiene intermediates with copper(II) chloride or AgIO(3)-Zn(OAc)(2). A dinaphthoporphyrin with two naphthalene units pointing toward one another could only be obtained in low yields due to a combination of stability and steric factors, but the other two adj-difused systems were isolated in good overall yields. However, the final dehydrogenation step occurred in moderate yields (50-60%) and could only be performed when the porphyrins bore propionate ester side chains that produced sufficient solubility in organic solvents. The two related opp-dinaphthoporphyrins were synthesized by a "head-to-tail" self-condensation of a dipyrrylmethane aldehyde, or a "3 + 1" synthesis using a tripyrrane intermediate bearing two fused dihydronaphthalene moieties, in excellent yields. In both cases, a final dehydrogenation step was required, but the opp-dinaphthoporphyrins were consistently formed in virtually quantitative yields. The opp-dinaphthoporphyrin series gave UV-vis spectra with relatively strong Soret bands at 425 nm, and the visible region was dominated by an unusually strong Q-band III. The adj-dinaphthoporphyrins produced broader less intense Soret bands and four well-defined Q-bands, including a relatively strong absorption at 645 nm. However, the relative orientation of the naphthalene rings had no significant effects on these spectra. On the other hand, the dications produced in TFA-chloroform solutions showed more discrimination between the individual porphyrin systems, and the metallo derivatives also displayed significant variations in their electronic absorption spectra.

Normal and Abnormal Heme Biosynthesis. 3.1Synthesis and Metabolism of Tripropionate Analogues of Coproporphyrinogen-III: Novel Probes for the Active Site of Coproporphyrinogen Oxidase

Coproporphyrinogen oxidase (copro'gen oxidase) catalyses the oxidative decarboxylation of two propionate side chains on coproporphyrinogen-III to produce protoporphyrinogen-IX. This process is very poorly understood at a molecular level, and copro'gen oxidase remains one of the least well-characterized enzymes in the heme biosynthetic pathway. To provide a rigorous test for a proposed model for substrate recognition and binding by this enzyme, two tripropionate analogues of copro'gen-III were prepared where an ethyl group replaced one of the usual propionate residues on positions 13 or 17. Although the required substrate probes are porphyrinogens (hexahydroporphyrins), the corresponding porphyrin methyl esters were initially synthesized via tripyrrene and a,c-biladiene intermediates. These were hydrolyzed and reduced with 3% sodium-amalgam to give the unstable porphyrinogens needed for the biochemical investigations. The modified structure with a 13-ethyl moiety was metabolized by avian preparations of copro'gen oxidase to give a monovinylic product, but the isomeric 17-ethylporphyrinogen afforded a divinylic product, albeit with poorer overall conversion. These results strongly support the proposed model for substrate binding at the active site of copro'gen oxidase.